Eylea Outperforms Avastin for Diabetic Macular Edema with Moderate or Worse Vision Loss

A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea (aflibercept) than for those receiving Avastin (bevacizumab), but only among participants starting treatment with 20/50 or worse vision. Gains after two years were about the same for Eylea and Lucentis (ranibizumab), contrary to year-one results from the study, which showed Eylea with a clear advantage. Language English
Source: News from NEI - Category: Opthalmology Authors: Source Type: news